(Reuters) - June 13 - Biovest International Inc. , a
majority unit of Accentia Biopharmaceuticals Inc. ,
said an independent panel reviewing its late-stage anti-cancer
vaccine trial found that there were no identifiable safety
concerns related to the therapy.
The Independent Data Monitoring Committee has requested an
interim analysis of all primary and secondary goals of
BiovaxID, the company said in a statement.
Read more at Reuters.com Government Filings News
majority unit of Accentia Biopharmaceuticals Inc. ,
said an independent panel reviewing its late-stage anti-cancer
vaccine trial found that there were no identifiable safety
concerns related to the therapy.
The Independent Data Monitoring Committee has requested an
interim analysis of all primary and secondary goals of
BiovaxID, the company said in a statement.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment